Medicines Australia welcomes reform efforts to speed up clinical trials

Australian patients will have improved access to clinical trials due to reforms to be introduced by the Australian government, following advocacy by pharma trade lobby Medicines Australia and other groups.

The ‘National One Stop Shop’ and the ‘National Clinical Trials Front Door’ reforms have just completed the first phase of consultation with peak bodies Medicines Australia, AusBiotech, and the Medical Technology Association of Australia (MTAA), via the R&D Taskforce. The co-chairs of the R&D Taskforce are David Wilks from Bristol Myers Squibb (NYSE: BMY) and Ana Svensson from Novo Nordisk (NOV: N).

Medicines Australia chief executive, Elizabeth de Somer, said these exciting reforms will significantly benefit patients and improve Australia’s international competitiveness in medical and scientific innovation.